Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

281.62 -3.56 (-1.25%)
Streaming Delayed Price Updated: 11:40 AM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
1 Mooning Stock to Target This Week and 2 We Brush Off
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
RMD Q2 Deep Dive: Margin Expansion and Product Innovation Drive Outperformance
Medical device company ResMed (NYSE:RMD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share... 
Via StockStory
Topics Artificial Intelligence Economy
ResMed Inc (NYSE:RMD): A Strong Dividend Stock with Growth Potential and Financial Stability
ResMed (RMD) offers a strong dividend with steady growth, backed by solid profitability and financial health, making it ideal for long-term income investors. 
Via Chartmill
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Discover the top S&P500 movers in Tuesday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
ResMed RMD Q4 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Stay informed with the top movers within the S&P500 index on Monday.
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
The Analyst Verdict: ResMed In The Eyes Of 8 Experts
 
Via Benzinga
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings
 
Via Benzinga
ResMed (RMD) Stock Is Up, What You Need To Know
Shares of medical device company ResMed (NYSE:RMD) jumped 3.1% in the afternoon session after the company reported strong fourth-quarter financial results that surpassed analyst estimates. 
Via StockStory
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
ResMed (NYSE:RMD) Surprises With Q2 Sales
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above... 
Via StockStory
Resmed Inc. (NYSE:RMD) Beats Q4 2025 Revenue and EPS Estimates Despite Muted Market Reaction
Resmed Inc. (NYSE:RMD) beats Q4 2025 revenue and EPS estimates, reporting $1.35B and $2.55, respectively. Stock dips slightly amid muted market reaction despite strong growth and dividend hike. 
Via Chartmill
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company ResMed (NYSE:RMD) will be reporting earnings this Thursday afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Analyst Expectations For ResMed's Future
 
Via Benzinga
2 Reasons to Watch RMD and 1 to Stay Cautious
ResMed trades at $254.11 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 5.4%. 
Via StockStory
Topics Government Stocks
Motley Fool Co-Founder David Gardner Reviews Stock Picks
Via The Motley Fool
2 S&P 500 Stocks with Promising Prospects and 1 to Steer Clear Of
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Economy Stocks
RESMED INC (NYSE:RMD) – A Strong Candidate for Quality Investors
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional ROIC, and solid cash flow, making it a standout pick for long-term investors. 
Via Chartmill
2 Cash-Producing Stocks to Consider Right Now and 1 to Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Looking Back on a Motley Fool Career
Via The Motley Fool
ResMed: A Mixed Bag for Investors Amid Rising Competition
Via The Motley Fool
RESMED INC (NYSE:RMD) – A Strong Contender for Quality Investors
RESMED INC (NYSE:RMD) is a high-quality stock with strong profitability, low debt, and consistent growth, making it a candidate for long-term investors. 
Via Chartmill
2 Large-Cap Stocks with Competitive Advantages and 1 to Approach with Caution
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Topics Fraud
3 Cash-Heavy Stocks with Competitive Advantages
Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. Without interest payments being less of a worry, these businesses can invest... 
Via StockStory
2 Healthcare Stocks to Keep an Eye On and 1 to Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
1 Surging Stock with Exciting Potential and 2 to Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved
RBC Capital noted that ResMed now has “a number of competitive threats on the horizon." 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.